Polyrizon Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $21.5M
- Price
- $10.30
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.81%
- Volume
- 23.2K
About
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Quick stats
Shares outstanding2.1M
Computed float1.8M
Float / shares88.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001893645
AI Summary
AI-generated1/21
minorbullishclinical trial
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Polyrizon completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker study, marking a significant operational milestone.
The planned first-in-human trial is designed to enroll up to 120 patients with seasonal allergic rhinitis to evaluate efficacy and safety versus a saline control.
Enrollment is timed to coincide with allergy seasons, shifting the focus to patient pre-screening and execution.